Altimmune, Inc. (NASDAQ: ALT) Appoints Gregory Weaver as Chief Financial OfficerGAITHERSBURG, MD – Altimmune, Inc. (Nasdaq: ALT) has recently named Gregory Weaver as its Chief Financial Officer (“CFO”), effective as of November 11, 2024. Weaver’s app

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Altimmune’s 8K filing here.

About Altimmune

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.